1. Sandrock C, Kelly T. Clinical review: update of avian influenza A infections in humans. Crit Care. 2007; 11:209.
Article
2. Lee NH, Lee JA, Park SY, Song CS, Choi IS, Lee JB. A review of vaccine development and research for industry animals in Korea. Clin Exp Vaccine Res. 2012; 1:18–34.
Article
3. Lee DH, Bae SW, Park JK, et al. Virus-like particle vaccine protects against H3N2 canine influenza virus in dog. Vaccine. 2013; 31:3268–3273.
Article
4. Lee DH, Park JK, Lee YN, et al. H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals. Vaccine. 2011; 29:4003–4007.
Article
5. Park JK, Lee DH, Youn HN, et al. Protective efficacy of crude virus-like particle vaccine against HPAI H5N1 in chickens and its application on DIVA strategy. Influenza Other Respir Viruses. 2013; 7:340–348.
Article
6. Prel A, Le Gall-Recule G, Jestin V. Achievement of avian influenza virus-like particles that could be used as a subunit vaccine against low-pathogenic avian influenza strains in ducks. Avian Pathol. 2008; 37:513–520.
Article
7. Pyo HM, Masic A, Woldeab N, et al. Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs. Vaccine. 2012; 30:1297–1304.
Article
8. Shen H, Xue C, Lv L, et al. Assembly and immunological properties of a bivalent virus-like particle (VLP) for avian influenza and Newcastle disease. Virus Res. 2013; 178:430–436.
Article
9. Fields BN, Knipe DM, Howley PM. Fields virology. 6th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health;2013.
10. Nayak B, Kumar S, DiNapoli JM, et al. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J Virol. 2010; 84:2408–2420.
Article
11. Alexander DJ. An overview of the epidemiology of avian influenza. Vaccine. 2007; 25:5637–5644.
Article
12. Saif YM, Fadly AM, Glisson JR, McDougald LR, Nolan LK, Swayne DE. Diseases of poultry. 12th ed. Ames: Blackwell Publishing;2008.
13. Butler D. Vaccination will work better than culling, say bird flu experts. Nature. 2005; 434:810.
Article
14. Swayne DE, Spackman E. Current status and future needs in diagnostics and vaccines for high pathogenicity avian influenza. Dev Biol (Basel). 2013; 135:79–94.
Article
15. Naeem K, Siddique N, Ayaz M, Jalalee MA. Avian influenza in Pakistan: outbreaks of low- and high-pathogenicity avian influenza in Pakistan during 2003-2006. Avian Dis. 2007; 51:1 Suppl. 189–193.
Article
16. Perk S, Panshin A, Shihmanter E, et al. Ecology and molecular epidemiology of H9N2 avian influenza viruses isolated in Israel during 2000-2004 epizootic. Dev Biol (Basel). 2006; 124:201–209.
17. Wu R, Sui ZW, Zhang HB, et al. Characterization of a pathogenic H9N2 influenza A virus isolated from central China in 2007. Arch Virol. 2008; 153:1549–1555.
Article
18. Zimmerman JJ, Karriker LA, Ramirez A, Schwartz KJ, Stevenson GW. Diseases of swine. 10th ed. Chichester: Wiley-Blackwell;2012.
19. Ma W, Kahn RE, Richt JA. The pig as a mixing vessel for influenza viruses: Human and veterinary implications. J Mol Genet Med. 2008; 3:158–166.
Article
20. Thacker E, Janke B. Swine influenza virus: zoonotic potential and vaccination strategies for the control of avian and swine influenzas. J Infect Dis. 2008; 197:Suppl 1. S19–S24.
Article
21. Houser RE, Heuschele WP. Evidence of prior infection with influenza A/Texas/77 (H3N2( virus in dogs with clinical parainfluenza. Can J Comp Med. 1980; 44:396–402.
22. Gibbs EP, Anderson TC. Equine and canine influenza: a review of current events. Anim Health Res Rev. 2010; 11:43–51.
Article
23. Songserm T, Amonsin A, Jam-on R, et al. Fatal avian influenza A H5N1 in a dog. Emerg Infect Dis. 2006; 12:1744–1747.
Article
24. Lin D, Sun S, Du L, et al. Natural and experimental infection of dogs with pandemic H1N1/2009 influenza virus. J Gen Virol. 2012; 93(Pt 1):119–123.
Article
25. Newton R, Cooke A, Elton D, et al. Canine influenza virus: cross-species transmission from horses. Vet Rec. 2007; 161:142–143.
Article
26. Li S, Shi Z, Jiao P, et al. Avian-origin H3N2 canine influenza A viruses in Southern China. Infect Genet Evol. 2010; 10:1286–1288.
Article
27. Song D, Lee C, Kang B, et al. Experimental infection of dogs with avian-origin canine influenza A virus (H3N2). Emerg Infect Dis. 2009; 15:56–58.
Article
28. Lee YN, Lee HJ, Lee DH, et al. Severe canine influenza in dogs correlates with hyperchemokinemia and high viral load. Virology. 2011; 417:57–63.
Article
29. Deshpande MS, Jirjis FF, Tubbs AL, et al. Evaluation of the efficacy of a canine influenza virus (H3N8) vaccine in dogs following experimental challenge. Vet Ther. 2009; 10:103–112.
30. Lee C, Jung K, Oh J, et al. Protective efficacy and immunogenicity of an inactivated avian-origin H3N2 canine influenza vaccine in dogs challenged with the virulent virus. Vet Microbiol. 2010; 143:184–188.
Article
31. Belshe RB. Current status of live attenuated influenza virus vaccine in the US. Virus Res. 2004; 103:177–185.
Article
32. Kang SM, Pushko P, Bright RA, Smith G, Compans RW. Influenza virus-like particles as pandemic vaccines. Curr Top Microbiol Immunol. 2009; 333:269–289.
Article
33. Haynes JR. Influenza virus-like particle vaccines. Expert Rev Vaccines. 2009; 8:435–445.
Article
34. Kang SM, Kim MC, Compans RW. Virus-like particles as universal influenza vaccines. Expert Rev Vaccines. 2012; 11:995–1007.
Article
35. Song H, Wittman V, Byers A, et al. In vitro stimulation of human influenza-specific CD8+ T cells by dendritic cells pulsed with an influenza virus-like particle (VLP) vaccine. Vaccine. 2010; 28:5524–5532.
Article
36. Hemann EA, Kang SM, Legge KL. Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination. J Immunol. 2013; 191:2486–2494.
Article
37. Wang BZ, Quan FS, Kang SM, Bozja J, Skountzou I, Compans RW. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol. 2008; 82:11813–11823.
Article
38. Crisci E, Barcena J, Montoya M. Virus-like particles: the new frontier of vaccines for animal viral infections. Vet Immunol Immunopathol. 2012; 148:211–225.
Article
39. Liu F, Ge S, Li L, Wu X, Liu Z, Wang Z. Virus-like particles: potential veterinary vaccine immunogens. Res Vet Sci. 2012; 93:553–559.
Article
40. Prel A, Le Gall-Recule G, Cherbonnel M, Grasland B, Amelot M, Jestin V. Assessment of the protection afforded by triple baculovirus recombinant coexpressing H5, N3, M1 proteins against a homologous H5N3 low-pathogenicity avian influenza virus challenge in Muscovy ducks. Avian Dis. 2007; 51:1 Suppl. 484–489.
Article
41. Suarez DL. Overview of avian influenza DIVA test strategies. Biologicals. 2005; 33:221–226.
Article
42. Meeusen EN, Walker J, Peters A, Pastoret PP, Jungersen G. Current status of veterinary vaccines. Clin Microbiol Rev. 2007; 20:489–510.
Article
43. Maeda S. Construction of recombinant baculoviruses carrying insect selective neurotoxin genes for pest insect control. Tanpakushitsu Kakusan Koso. 1992; 37:842–847.
44. Margine I, Martinez-Gil L, Chou YY, Krammer F. Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity. PLoS One. 2012; 7:e51559.
Article
45. Lua LH, Connors NK, Sainsbury F, Chuan YP, Wibowo N, Middelberg AP. Bioengineering virus-like particles as vaccines. Biotechnol Bioeng. 2014; 111:425–440.
Article
46. Pushko P, Pearce MB, Ahmad A, et al. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine. 2011; 29:5911–5918.
Article